| Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial C Mowat, I Arnott, A Cahill, M Smith, T Ahmad, S Subramanian, S Travis, ... The lancet Gastroenterology & hepatology 1 (4), 273-282, 2016 | 110 | 2016 |
| A prospective single‐centre evaluation of the intra‐individual variability of faecal calprotectin in quiescent C rohn's disease GD Naismith, LA Smith, SJE Barry, JI Munro, S Laird, K Rankin, AJ Morris, ... Alimentary pharmacology & therapeutics 37 (6), 613-621, 2013 | 90 | 2013 |
| A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease GD Naismith, LA Smith, SJE Barry, JI Munro, S Laird, K Rankin, AJ Morris, ... Journal of Crohn's and Colitis 8 (9), 1022-1029, 2014 | 65 | 2014 |
| Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish vedolizumab cohort N Plevris, CS Chuah, RM Allen, ID Arnott, PN Brennan, S Chaudhary, ... Journal of Crohn's and Colitis 13 (9), 1111-1120, 2019 | 42 | 2019 |
| The financial impact of a nurse-led telemedicine service for inflammatory bowel disease in a large district general hospital SI Squires, AJ Boal, GD Naismith Frontline Gastroenterology 7 (3), 216-221, 2016 | 29 | 2016 |
| Real‐world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort N Plevris, J Fulforth, S Siakavellas, A Robertson, R Hall, A Tyler, ... Journal of gastroenterology and hepatology 36 (8), 2067-2075, 2021 | 20 | 2021 |
| Implementing a self-management strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes and the impact on service SI Squires, AJ Boal, S Lamont, GD Naismith Frontline gastroenterology 8 (4), 272-278, 2017 | 18 | 2017 |
| Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents K Karmiris, P Bossuyt, D Sorrentino, T Moreels, A Scarcelli, J Legido, ... Journal of Crohn's and Colitis 9 (5), 382-389, 2015 | 6 | 2015 |
| Optimising IBD patient selection for de-escalation of anti-TNF therapy to immunomodulator maintenance R Swann, A Boal, SI Squires, C Lamb, LL Clark, S Lamont, G Naismith Frontline Gastroenterology 11 (1), 16-21, 2020 | 5 | 2020 |
| Implementing a self-management strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes and the impact on service. Frontline Gastroenterol. 2017; 8 … SI Squires, AJ Boal, S Lamont, GD Naismith | 5 | |
| Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s … NT Ventham, NA Kennedy, R Kalla, AT Adams, A Noble, H Ennis, I Arnott, ... Cellular and Molecular Gastroenterology and Hepatology 16 (3), 431-450, 2023 | 3 | 2023 |
| Combining NICE guidelines with exclusion criteria to identify patients with Crohn's disease for treatment withdrawal: 12-month prospective cohort study S Squires, G Naismith, A Boal Gastrointestinal Nursing 14 (2), 20-28, 2016 | 3 | 2016 |
| PWE-045 Vedolizumab results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish Vedolizumab Cohort N Plevris, C Chuah, P Jenkinson, R Allen, P Baker, P Brennan, ... Gut 67 (Suppl 1), A89-A90, 2018 | 2 | 2018 |
| P575 real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: the scottish ustekinumab cohort N Plevris, A Robertson, J Fulforth, R Hall, I Campbell, C Kane, J Veryan, ... Journal of Crohn's and Colitis 14 (Supplement_1), S484-S484, 2020 | 1 | 2020 |
| PTH-104 Anti-tnf drug and antibody testing at week 30 in patients with inflammatory bowel disease: is it worthwhile? A Boal, SI Squires, GD Naismith Gut 66 (Suppl 2), A257-A258, 2017 | 1 | 2017 |
| PTH-071 Prospective anti-tnf withdrawal in quiescent crohn's disease-12 month clinical outcomes S Squires, A Boal, R Hamid, M Heydtmann, G Naismith Gut 64, A437, 2015 | 1 | 2015 |
| PWE-104 The Financial Impact Of A Nurse-led Ibd (inflammatory Bowel Disease) Telephone Advice Service, In A Large District General Hospital S Squires, A Boal, G Naismith Gut 63 (Suppl 1), A170-A170, 2014 | 1 | 2014 |
| Mo1690 A Prospective Single Centre Evaluation of the Intra-Individual Variability of Faecal Calprotectin in Quiescent Crohn's Disease Patients LA Smith, G Naismith, JI Munro, K Rankin, S Barry, AJ Morris, JW Winter, ... Gastroenterology 5 (142), S-660, 2012 | 1 | 2012 |
| P17 IBD admission avoidance during COVID-19 J Cousin, A Boal, S Squires, G Naismith Gut 71 (Suppl 1), A44-A45, 2022 | | 2022 |
| P135 Real-world effectiveness and safety of ustekinumab for the treatment of crohn’s: the Scottish ustekinumab cohort N Plevris, A Robertson, J Fulforth, R Hall, P Jenkinson, I Campbell, ... Gut 70 (Suppl 1), A112-A113, 2021 | | 2021 |
